DeCure for Hypomaturation-hypoplastic amelogenesis imperfecta with taurodontism
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for hypomaturation-hypoplastic amelogenesis imperfecta with taurodontism — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleHypomaturation-hypoplastic amelogenesis imperfecta with taurodontism maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for hypomaturation-hypoplastic amelogenesis imperfecta with taurodontism is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
A 2005 study mapped a family with autosomal dominant hypomaturation-hypoplastic amelogenesis imperfecta with taurodontism (AIHHT) to chromosome 17q21-q22 with a lod score of 3.3. A two-basepair deletion (CT) at nucleotide 560 in the DLX3 gene was identified. This deletion causes a frameshift that alters the last two amino acids of the DNA-binding homeodomain and introduces a premature stop codon, truncating the protein by 88 amino acids. The authors note that a previous DLX3 mutation outside the homeodomain had been associated with tricho-dento-osseous syndrome (TDO), suggesting that TDO and some forms of AIHHT are allelic.
A 1990 review examined the confusion between diagnoses of amelogenesis imperfecta with taurodontism and tricho-dento-osseous syndrome. The authors proposed criteria to distinguish the two conditions after a critical review of the literature and correspondence with original authors. No genetic or molecular data were presented in that review.
A 1978 report described taurodontism with hypoplastic/hypomature enamel defects in two cases of X-chromosome aneuploidy (47,XXY) and one case of X-linked recessive amelogenesis imperfecta. The authors observed that the degree of taurodontism increased with the number of X chromosomes and suggested the X-chromosome plays a role in both tooth size and enamel maturation. No specific gene or mutation was identified.
No clinical trial, treatment, or drug is mentioned in any of these abstracts. What is missing is any molecular understanding of how the DLX3 mutation leads to the enamel and pulp phenotype, a suitable animal model for testing interventions, and any funding or trial design aimed at correcting the defect in patients. Patient stratification by specific DLX3 mutation versus other genetic causes has not been attempted in a therapeutic context.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
American Journal of Medical Genetics Part A · 2005 · 141 citations
DLX3 mutation associated with autosomal dominant amelogenesis imperfecta with taurodontism
AbstractAmelogenesis imperfecta hypoplastic-hypomaturation with taurodontism (AIHHT) is an autosomal dominant (AD) trait associated with enamel defects and enlarged pulp chambers. In this study, we mapped an AIHHT family to human chromosome 17 q21-q22 (lod score 3.3) and identify a two basepair deletion (CT) at nucleotide 560 in DLX3 associated with the disease. This mutation causes a frameshift altering the last two amino acids of the DNA-binding homeodomain introducing a premature stop codon truncating the protein by 88 amino acids. This is the first report of a mutation within the homeodomain of DLX3. Previous studies have shown a DLX3 mutation outside the homeodomain associated with tricho-dento-osseous syndrome (TDO) suggesting TDO and some forms of AIHHT are allelic.
Amelogenesis imperfecta with taurodontism and the tricho‐dento‐osseous syndrome: separate conditions or a spectrum of disease?
AbstractVarious authors have allocated a diagnosis of tricho-dento-osseous syndrome to cases originally reported as amelogenesis imperfecta (hypomaturation-hypoplasia type) with taurodontism. The resulting confusion has prompted this critical review of the literature, and further information has been obtained from the authors concerned. Criteria for diagnosis of the two conditions are proposed.
Taurodontism and enamel hypomaturation associated with X‐linked abnormalities
AbstractThe association of taurodontism with hypoplastic/hypomature enamel defects is presented in two cases of X-chromosome aneuploidy (47,XXY) and one of X-linked recessive Amelogenesis Imperfecta. It appears that the X-chromosome not only plays some role in tooth size the degree of taurodontism increasing with increased number of X chromosomes), but probably also plays a role in enamel maturation.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
